Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DHR Stock Forecast 2026-2027
$194.75
Current Price
$137.82B
Market Cap
Buy 22
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to DHR Price Targets
+59.2%
To High Target of $310.00
+34.8%
To Median Target of $262.50
+5.3%
To Low Target of $205.00
DHR Price Momentum
-0.6%
1 Week Change
+2.9%
1 Month Change
+4.2%
1 Year Change
-14.9%
Year-to-Date Change
-19.8%
From 52W High of $242.80
+8.2%
From 52W Low of $180.03
📊 TOP ANALYST CALLS
Did DHR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Danaher is one of their latest high-conviction picks.
Latest DHR Stock Price Targets & Analyst Predictions
Based on our analysis of 39 Wall Street analysts, DHR has a bullish consensus with a median price target of $262.50 (ranging from $205.00 to $310.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $194.75, the median forecast implies a 34.8% upside. This outlook is supported by 22 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 59.2% upside. Conversely, the most conservative target is provided by Brandon Couillard at Wells Fargo, suggesting a 5.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DHR Analyst Ratings
22
Buy
3
Hold
0
Sell
DHR Price Target Range
Low
$205.00
Average
$262.50
High
$310.00
Current: $194.75
Latest DHR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DHR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2026 | Baird | Catherine Schulte | Outperform | Maintains | $249.00 |
| Apr 14, 2026 | Barclays | Luke Sergott | Overweight | Maintains | $230.00 |
| Apr 13, 2026 | Goldman Sachs | Evie Koslosky | Buy | Maintains | $230.00 |
| Apr 6, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $225.00 |
| Jan 29, 2026 | Jefferies | Tycho Peterson | Buy | Maintains | $265.00 |
| Jan 29, 2026 | JP Morgan | Tycho Peterson | Overweight | Maintains | $275.00 |
| Jan 7, 2026 | TD Cowen | Dan Brennan | Buy | Maintains | $270.00 |
| Jan 5, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $275.00 |
| Dec 15, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $240.00 |
| Dec 9, 2025 | Goldman Sachs | Evie Koslosky | Buy | Initiates | $265.00 |
| Dec 2, 2025 | Morgan Stanley | Kallum Titchmarsh | Overweight | Initiates | $270.00 |
| Oct 23, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $230.00 |
| Oct 22, 2025 | TD Cowen | Dan Brennan | Buy | Maintains | $260.00 |
| Oct 22, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $250.00 |
| Oct 8, 2025 | Rothschild & Co | Ed Ridley-Day | Neutral | Downgrade | $220.00 |
| Oct 7, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $245.00 |
| Sep 22, 2025 | B of A Securities | Derik De Bruin | Buy | Maintains | $220.00 |
| Jul 23, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $205.00 |
| Jul 23, 2025 | UBS | Dan Leonard | Buy | Maintains | $225.00 |
| Jul 23, 2025 | Baird | Catherine Schulte | Outperform | Maintains | $229.00 |
Danaher Corporation (DHR) Competitors
The following stocks are similar to Danaher based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DHR
Danaher
mkt cap
137.82B
Danaher Corporation (DHR) Financial Data
Danaher Corporation has a market capitalization of $137.82B with a P/E ratio of 38.8x. The company generates $24.57B in trailing twelve-month revenue with a 14.7% profit margin.
Revenue growth is +4.6% quarter-over-quarter, while maintaining an operating margin of +22.2% and return on equity of +7.1%.
Valuation Metrics
Market Cap
$137.82B
Enterprise Value
$152.80B
P/E Ratio
38.8x
PEG Ratio
3.1x
Price/Sales
5.6x
Growth & Margins
Revenue Growth (YoY)
+4.6%
Gross Margin
+58.0%
Operating Margin
+22.2%
Net Margin
+14.7%
EPS Growth
+10.2%
Financial Health
Cash/Price Ratio
+3.4%
Current Ratio
1.9x
Debt/Equity
37.5x
ROE
+7.1%
ROA
+4.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Danaher Corporation (DHR) Business Model
About Danaher Corporation
What They Do
Designs and markets healthcare and industrial products.
Business Model
The company operates through three main segments: Biotechnology, Life Sciences, and Diagnostics. It generates revenue by providing a range of bioprocessing technologies and consumables that enhance therapeutic development and manufacturing processes. Additionally, it offers advanced research tools and essential healthcare filtration solutions.
Additional Information
Founded in 1969, Danaher has undergone significant transformation through strategic acquisitions and divestitures, including the recent spin-off of its environmental solutions. With a workforce of approximately 62,000 to 63,000 employees and led by CEO Rainer Blair, Danaher is a key player in the healthcare and life sciences sectors, focusing on innovation and recurring revenue streams.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
58,000
CEO
Mr. Rainer M. Blair
Country
United States
IPO Year
1987
Website
www.danaher.comDanaher Corporation (DHR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Danaher Gears Up to Post Q1 Earnings: What Lies Ahead for the Stock?
DHR heads into Q1 results with rising bioprocessing demand and steady estimates, but cost pressures and FX headwinds could weigh on performance.
Apr 16, 2026
By Zacks Equity Research
Analyst Blog
Danaher (DHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 14, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Danaher (DHR) may not meet earnings expectations in its upcoming report due to a lack of the necessary factors for a potential earnings beat.
Why It Matters
Danaher's lack of key indicators for an earnings beat may signal weaker performance, potentially affecting stock prices and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Danaher (DHR) is set to report its Q1 2026 performance. Investors should focus on key metrics beyond typical revenue and earnings estimates for deeper insights.
Why It Matters
Evaluating Danaher's performance beyond traditional estimates offers insights into growth potential, operational efficiency, and market positioning, critical for informed investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
DHR is poised for Q1 results amid increasing bioprocessing demand and stable estimates, though cost pressures and FX headwinds may impact performance.
Why It Matters
Rising bioprocessing demand may boost DHR's growth, but cost pressures and FX challenges could impact profitability, influencing investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Mar Vista's U.S. Quality Premier strategy declined 10.17% in Q1 2026, underperforming the Russell 1000 and S&P 500. Johnson & Johnson rose 18.74%, and Taiwan Semiconductor raised its outlook amid strong demand.
Why It Matters
Mar Vista's underperformance relative to major indices signals potential concerns about its strategy. In contrast, strong gains from Johnson & Johnson and Taiwan Semiconductor highlight opportunities in specific sectors.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
Beckman Coulter Diagnostics has received CE mark for the Access MeMed BV assay, which could save European health systems up to €80M by reducing unnecessary admissions and testing.
Why It Matters
The new MeMed BV assay could significantly reduce healthcare costs in Europe by minimizing unnecessary admissions and tests, potentially enhancing profitability for healthcare providers and related investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Shareholders can consult the firm about their rights and options at no cost, with legal fees covered on a contingent basis, meaning no upfront payment is required.
Why It Matters
This indicates potential legal issues for the firm, which could impact its stock price and shareholder value. Investors may need to assess risk exposure and potential liabilities.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DHR Stock
What is Danaher Corporation's (DHR) stock forecast for 2026?
Based on our analysis of 39 Wall Street analysts, Danaher Corporation (DHR) has a median price target of $262.50. The highest price target is $310.00 and the lowest is $205.00.
Is DHR stock a good investment in 2026?
According to current analyst ratings, DHR has 22 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $194.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DHR stock?
Wall Street analysts predict DHR stock could reach $262.50 in the next 12 months. This represents a 34.8% increase from the current price of $194.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Danaher Corporation's business model?
The company operates through three main segments: Biotechnology, Life Sciences, and Diagnostics. It generates revenue by providing a range of bioprocessing technologies and consumables that enhance therapeutic development and manufacturing processes. Additionally, it offers advanced research tools and essential healthcare filtration solutions.
What is the highest forecasted price for DHR Danaher Corporation?
The highest price target for DHR is $310.00 from Paul Knight at Keybanc, which represents a 59.2% increase from the current price of $194.75.
What is the lowest forecasted price for DHR Danaher Corporation?
The lowest price target for DHR is $205.00 from Brandon Couillard at Wells Fargo, which represents a 5.3% increase from the current price of $194.75.
What is the overall DHR consensus from analysts for Danaher Corporation?
The overall analyst consensus for DHR is bullish. Out of 39 Wall Street analysts, 22 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $262.50.
How accurate are DHR stock price projections?
Stock price projections, including those for Danaher Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 12:44 PM UTC